Cambrex Corporation (CBM) Given Average Recommendation of “Buy” by Brokerages
Shares of Cambrex Corporation (NYSE:CBM) have earned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $64.00.
A number of research firms have recently commented on CBM. ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub upgraded shares of Cambrex Corporation from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Investment Research upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price objective for the company in a research report on Thursday, May 11th.
ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/06/12/cambrex-corporation-cbm-given-average-recommendation-of-buy-by-brokerages.html.
Shares of Cambrex Corporation (CBM) traded up 0.35% during trading on Monday, hitting $58.00. 60,328 shares of the stock traded hands. The company has a market cap of $1.89 billion, a P/E ratio of 22.08 and a beta of 2.42. The stock has a 50-day moving average of $54.99 and a 200 day moving average of $53.85. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.17. Cambrex Corporation had a net margin of 17.36% and a return on equity of 24.92%. The company had revenue of $105.01 million during the quarter, compared to analyst estimates of $99.05 million. During the same period last year, the business earned $0.50 earnings per share. Cambrex Corporation’s revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts predict that Cambrex Corporation will post $3.02 EPS for the current fiscal year.
In related news, Director Leon J. Hendrix, Jr. sold 20,656 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $55.95, for a total value of $1,155,703.20. Following the sale, the director now directly owns 74,662 shares of the company’s stock, valued at $4,177,338.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $54.58, for a total transaction of $654,960.00. Following the completion of the sale, the chief executive officer now directly owns 95,328 shares in the company, valued at $5,203,002.24. The disclosure for this sale can be found here. Insiders sold 56,656 shares of company stock worth $3,159,343 over the last ninety days. 2.48% of the stock is currently owned by insiders.
A number of large investors have recently made changes to their positions in the stock. Flinton Capital Management LLC increased its stake in shares of Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares in the last quarter. YorkBridge Wealth Partners LLC increased its stake in shares of Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Cambrex Corporation during the first quarter valued at approximately $109,000. Dubuque Bank & Trust Co. acquired a new position in Cambrex Corporation during the first quarter valued at approximately $144,000. Finally, Ameritas Investment Partners Inc. acquired a new position in Cambrex Corporation during the first quarter valued at approximately $151,000. 98.28% of the stock is currently owned by institutional investors and hedge funds.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.